Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ocular Therapeutix

8.95
+0.13001.47%
Post-market: 9.200.2500+2.79%16:34 EDT
Volume:1.97M
Turnover:17.08M
Market Cap:1.43B
PE:-7.78
High:9.05
Open:8.77
Low:8.44
Close:8.82
Loading ...

Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside

Benzinga
·
12 Mar

Needham Initiates Ocular Therapeutix at Buy With $15 Price Target

MT Newswires Live
·
11 Mar

Ocular Therapeutix Initiated at Buy by Needham

Dow Jones
·
11 Mar

Ocular Therapeutix initiated with a Buy at Needham

TIPRANKS
·
11 Mar

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
08 Mar

Stock Track | Ocular Therapeutix Soars 5% as AXPAXLI Trial Updates Boost Dosing Flexibility Prospects, Timelines

Stock Track
·
04 Mar

Ocular Therapeutix Is Maintained at Market Outperform by Citizens Capital Markets

Dow Jones
·
04 Mar

Scotiabank Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)

TIPRANKS
·
04 Mar

Ocular Therapeutix Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow Jones
·
04 Mar

Ocular Therapeutix price target lowered to $19 at Citizens JMP, buy on weakness

TIPRANKS
·
04 Mar

Ocular Therapeutix Inc (OCUL) Q4 2024 Earnings Call Highlights: Strategic Advancements and ...

GuruFocus.com
·
04 Mar

Ocular Therapeutix Inc. Faces Operational Risks Amid Regulatory Delays and Government Disruptions

TIPRANKS
·
04 Mar

Q4 2024 Ocular Therapeutix Inc Earnings Call

Thomson Reuters StreetEvents
·
04 Mar

Ocular Therapeutix Reports 2024 Financial Results and Progress

TIPRANKS
·
04 Mar

Ocular Therapeutix Earnings Call Highlights Progress and Challenges

TIPRANKS
·
04 Mar

Ocular Therapeutix: Strategic Amendments and Financial Strength Justify Buy Rating

TIPRANKS
·
04 Mar

BUZZ-Ocular slides on Q4 revenue miss

Reuters
·
04 Mar

Ocular Therapeutix Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
03 Mar

Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
03 Mar

Ocular Therapeutix Q4 Net Loss Narrows, Revenue Rises

MT Newswires Live
·
03 Mar